AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.

Обзор

This program initially aims to recruit 1300 breast cancer patients from a large number of hospitals across Europe. Eligible patients are those who are 18 or older, either female or male, and who have not received more than 1 type of treatment from the time metastases were discovered, metastasi(e)s has just been diagnosed or their disease has come back (disease relapse). Biopsy samples from both the primary and metastatic (or relapsed) tumor will be collected for central analyses, together with blood, serum and plasma samples. Any samples not analyzed immediately will be stored in an independent bio-repository to enable future (not yet defined) research aimed at better understanding metastatic breast cancer. In summary, the main objectives of AURORA are to better understand the genetic aberrations in metastatic breast cancer and to discover the mechanisms of response or resistance to therapy, in order to ultimately identify the "right therapy for each individual patient". At the same time, patients with genetic aberrations that are being targeted by new drugs in development will be offered the possibility to participate in clinical trials, when approved and available in their countries. Ultimately, the aim of AURORA is to improve the outcomes of all patients diagnosed with metastatic breast cancer.

Вмешательства

• Процедура metastatic lesion biopsy
  a medical test commonly performed by a surgeon or an interventional radiologist in order to collect tissues for examination; in this case from a metastatic lesion

Первичные конечные точки

• Metastatic Breast Cancer (MBC) understanding [Срок оценки: 1 year after end of acrrual]

Вторичные конечные точки (6)

• Identification of "exceptional responders" and "rapid progressors"; the outlier patients [Срок оценки: 1 year after end of accrual and subsequently during follow up period of 10 years]
• Feasibility of implementing a global molecular screening platform for MBC [Срок оценки: 1 year after end of accrual]
• Patient identification to match with biomarker-driven clinical trials [Срок оценки: on ongoing basis during 3 years' patient recruitment]
• Building new therapeutic hypotheses [Срок оценки: 1 year after end of accrual and subsequently during follow up period of 10 years]
• Patients' prognosis determination [Срок оценки: 1 year after end of accrual and subsequently during follow up period of 10 years]
• Correlation between molecular alterations and standardly assessed efficacy endpoints [Срок оценки: 1 year after end of accrual and subsequently during follow up period of 10 years]

Критерии участия

Критерии включения

• Female or male ≥ 18 years with diagnosis of locally recurrent/advanced BC not amenable to treatment with curative intent or MBC who have not received more than 1 line of systemic therapy (any type) in the metastatic setting.

Under protocol 4.0, eligible patients will be limited to locally recurrent/advanced breast cancer not amenable to treatment with curative intent or MBC with:

• histopathology-confirmed TNBC as defined by ER <1% and HER2 negative following ASCO-CAP guidelines
• ILC (either based on ILC morphology or negative E-cadherin expression confirmed by IHC). Mixed ILC/invasive ductal carcinoma are not eligible for the ILC cohort.
• late relapse BC (any subtype). Late relapse is defined as a patient with a radiologic or histologic confirmation of advanced or MBC relapse > 10 years from the primary BC diagnosis.
• Written informed consent prior to registration into the program.
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
• Availability of primary tumor tissue for research purposes.
• Patient must have a metastatic lesion accessible for biopsy and must agree with the biopsy procedure.

• Up until protocol 3.0, up to 100 patients with bone-only metastasis have been included without a metastatic biopsy, if plasma samples have been collected at screening, and if the patient met all other eligibility criteria.
• In protocol 4.0, metastatic tumor biopsies from bone lesions will be accepted provided that the chosen site of biopsy was not previously irradiated.
• Brain tissue is accepted if it is obtained through surgical excision not planned for AURORA, but as part of the routine clinical practice.
• The biopsy of the metastatic lesion must be conducted either at the initial diagnosis of the BC relapse before the initiation of 1st line systemic therapy or at the 1st disease progression before initiation of a second line systemic treatment. There is no restriction in the type of therapeutic modality considered as 1st line systemic treatment, which can consist of any type of treatment administered after the diagnosis of the advanced BC relapse till the 1st disease progression thereafter.
• Biopsies obtained during routine clinical practice are accepted if both formalin-fixed paraffin-embedded (FFPE) and Frozen Tissue (FT) blocks were collected concurrently from the same metastatic lesion and if collected at the pre-specified timelines for AURORA.
• Availability of a whole blood, serum and plasma samples collected at the time of screening.
• Patient agrees to provide blood samples at regular intervals, from the screening as well as during the follow-up phase of the program.

Критерии исключения

• The patient has received more than 1 line of systemic therapy (any type) in the metastatic setting.
• Patients who have received prior palliative radiotherapy to the only site that is accessible to biopsy.
• Presence of severe hematopoietic, renal, and/or hepatic dysfunction, including but not restricted to albumin < 3 g/dl.
• Known increased risk of hemorrhage during biopsy procedure, as evaluated by the treating physician.
• Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Скрининг

Центры проведения

Испания · 15 центров

• Complexo Hospitalario Universitario A Coruña — A Coruña
• Hospital del Mar — Barcelona
• Dr Rosell Oncology Institute, Quirón Dexeus University Hospital — Barcelona
• Hospital Vall d'Hebron — Barcelona
• Consorcio Hospitalario Provincial de Castellón — Castellon
• Hospital San Pedro de Alcantara — Cáceres
• Hospital Universitari Arnau de Vilanova — Lleida
• MD Anderson Cancer Center — Madrid
• … и ещё 7 центров

Великобритания · 11 центров

• Queen Elizabeth Hospital - University Hospitals Birmingham NHS Foundation Trust — Birmingham
• University Hospitals Bristol NHS Foundation Trust — Bristol
• Velindre NHS Trust — Cardiff
• NHS Tayside, Ninewells Hospital — Dundee
• Edinburgh Cancer Centre - Western General Hospital — Edinburgh
• Beatson West of Scotland Cancer Centre — Glasgow
• Christie NHS Foundation Trust — Manchester
• Nottingham University Hospital NHS Trust — Nottingham
• … и ещё 3 центра

Италия · 9 центров

• Ospedale degli Infermi - S.O.C.Oncologia — Biella
• Ospedale di Bolzano - Oncologia Medica — Bolzano
• Ospedale Ramazzini di Carpi — Carpi
• IRCCS AOU San Martino-IST — Genova
• ULSS 21 Legnago — Legnago
• Istituto Europeo di Oncologia — Milan
• UOC Oncologia Medica - AOU Parma — Parma
• Fondazione Salvatore Maugeri — Pavia
• … и ещё 1 центр

Бельгия · 6 центров

• Institut Jules Bordet — Brussels
• Cliniques Universitaires St-Luc — Brussels
• Grand Hopital Charleroi — Charleroi
• UZ Leuven — Leuven
• CHU de Liège — Liège
• Clinique et Maternité Sainte-Elisabeth (CMSE - Namur) — Namur

Швейцария · 4 центра

• Kantonsspital Baden — Baden
• Inselspital Bern — Bern
• Kantonsspital Graubuenden — Chur
• Luzerner Kantonsspital, Division of Medical Oncology — Lucerne

Германия · 2 центра

• Kliniken Essen-Mitte, Klinik für Senologie/ Brustzentrum — Essen
• Frauenkliniken Maistrasse-Innenstadt und Großhadern — München

Швеция · 2 центра

• Sahlgrenska University Hospital — Gothenburg
• Ryhov County Hospital — Jönköping

Iceland · 1 центр

• Landspitali — Reykjavik

Luxembourg · 1 центр

• Centre Hospitalier — Luxembourg

Португалия · 1 центр

• Champalimaud Foundation — Lisbon

Идентификаторы

NCT: NCT02102165 · BIG 14-01 · 1408-BCG · GBG 85 · ICR-CTSU/2014/10050

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗